Researchers combined bacteriophage therapy with antibiotics to successfully treat refractory peritoneal dialysis‑associated peritonitis caused by Klebsiella pneumoniae in a Nature Communications study. The combo overcame multidrug resistance in experimental models and resolved infections that standard antibiotics could not, demonstrating a route to repurpose phages as adjunctive tools in difficult‑to‑treat, device‑associated infections. The work details potency, dosing synergy, and mechanistic insights, and it frames phage–antibiotic regimens as candidates for compassionate‑use studies and tightly controlled clinical trials in dialysis and other high‑risk settings.